November 20, 2017
The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according to Celgene Corporation and bluebird bio, the companies developing the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy. In a press release, the companies reported that the investigational agent had also been awarded PRIority MEdicines...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand